Lung Transplantation: Advances in Immunosuppression

Errol L. Bush; Shu S. Lin

doi:10.1016/j.thorsurg.2006.07.002

Lung Transplantation: Advances in Immunosuppression

Errol L. Bush, Shu S. Lin

Research output: Contribution to journal › Review article › peer-review

4 Scopus citations

Abstract

Since the advent of various novel immunosuppressants, including tacrolimus, rapamycin, and daclixumab, expanding variations of protocols have been developed. Little evidence exists to substantially support a single agent over another, or a combination regimen protocol over another. Therefore, the principles and the goals of immunosuppression in lung transplantation recipients will remain moving targets and continue to evolve, and the use of large-scale, multi-institutional clinical trials is imperative to develop optimal immunosuppressive strategies.

Original language	English (US)
Pages (from-to)	421-433
Number of pages	13
Journal	Thoracic surgery clinics
Volume	16
Issue number	4
DOIs	https://doi.org/10.1016/j.thorsurg.2006.07.002
State	Published - Nov 1 2006
Externally published	Yes

ASJC Scopus subject areas

Surgery
Pulmonary and Respiratory Medicine

Access to Document

10.1016/j.thorsurg.2006.07.002

Cite this

@article{85683f5263a243bf98a0a6929478de45,

title = "Lung Transplantation: Advances in Immunosuppression",

abstract = "Since the advent of various novel immunosuppressants, including tacrolimus, rapamycin, and daclixumab, expanding variations of protocols have been developed. Little evidence exists to substantially support a single agent over another, or a combination regimen protocol over another. Therefore, the principles and the goals of immunosuppression in lung transplantation recipients will remain moving targets and continue to evolve, and the use of large-scale, multi-institutional clinical trials is imperative to develop optimal immunosuppressive strategies.",

author = "Bush, {Errol L.} and Lin, {Shu S.}",

year = "2006",

month = nov,

day = "1",

doi = "10.1016/j.thorsurg.2006.07.002",

language = "English (US)",

volume = "16",

pages = "421--433",

journal = "Thoracic surgery clinics",

issn = "1547-4127",

publisher = "W.B. Saunders Ltd",

number = "4",

}

TY - JOUR

T1 - Lung Transplantation

T2 - Advances in Immunosuppression

AU - Bush, Errol L.

AU - Lin, Shu S.

PY - 2006/11/1

Y1 - 2006/11/1

N2 - Since the advent of various novel immunosuppressants, including tacrolimus, rapamycin, and daclixumab, expanding variations of protocols have been developed. Little evidence exists to substantially support a single agent over another, or a combination regimen protocol over another. Therefore, the principles and the goals of immunosuppression in lung transplantation recipients will remain moving targets and continue to evolve, and the use of large-scale, multi-institutional clinical trials is imperative to develop optimal immunosuppressive strategies.

AB - Since the advent of various novel immunosuppressants, including tacrolimus, rapamycin, and daclixumab, expanding variations of protocols have been developed. Little evidence exists to substantially support a single agent over another, or a combination regimen protocol over another. Therefore, the principles and the goals of immunosuppression in lung transplantation recipients will remain moving targets and continue to evolve, and the use of large-scale, multi-institutional clinical trials is imperative to develop optimal immunosuppressive strategies.

UR - http://www.scopus.com/inward/record.url?scp=37849189132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37849189132&partnerID=8YFLogxK

U2 - 10.1016/j.thorsurg.2006.07.002

DO - 10.1016/j.thorsurg.2006.07.002

M3 - Review article

C2 - 17240827

AN - SCOPUS:37849189132

SN - 1547-4127

VL - 16

SP - 421

EP - 433

JO - Thoracic surgery clinics

JF - Thoracic surgery clinics

IS - 4

ER -

Lung Transplantation: Advances in Immunosuppression

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this